首页> 外文期刊>CVIR Endovascular >Splenic vein stenting for recurrent chylous ascites in sinistral portal hypertension: a case report
【24h】

Splenic vein stenting for recurrent chylous ascites in sinistral portal hypertension: a case report

机译:在Sinistral门户高血压中进行复发性Chylous腹水的脾静脉支撑:案例报告

获取原文
获取外文期刊封面目录资料

摘要

Sinistral portal hypertension results from obstruction or stenosis of the splenic vein and is characterized by normal portal vein pressures and liver function tests. Gastrointestinal bleeding is the most common presentation and indication for treatment. Although sinistral portal hypertension-related chylous ascites is rare, several cases have described successful treatment with portal venous, rather than splenic venous, recanalization. Splenectomy is effective in the treatment of sinistral portal hypertension-related bleeding, although recent studies have evaluated splenic vein stenting and splenic arterial embolization as minimally-invasive treatment alternatives. Splenic vein stenting may be a viable option for other presentations of sinistral portal hypertension. A 59-year-old gentleman with a history of necrotizing gallstone pancreatitis was referred to interventional radiology for management of recurrent chylous ascites. Analysis of ascites demonstrated a triglyceride level of 1294?mg/dL. Computed tomography revealed splenic and superior mesenteric venous stricture. The patient elected to undergo minimally invasive transhepatic portal venography, which confirmed the presence of splenic vein and superior mesenteric vein stenosis. Venography of the splenic vein showed reversal of portal venous flow, multiple collaterals, and a pressure gradient of 14?mmHg. Two 10?mm?×?40?mm Cordis stents were placed, which decreased the pressure gradient to 7?mmHg and resolved the portosystemic collaterals. At 6?months follow-up, the patient had no recurrent episodes of ascites. The current case highlights the successful treatment of sinistral portal hypertension-related intractable chylous ascites treated with transhepatic splenic vein stenting. Splenic venous stent patency rates of 92.9% at 12 months have been reported. Rebleeding rates of 7.1% for splenic vein stenting, 16% for splenectomy, and 47.8% for splenic arterial embolization have been reported in the treatment of sinistral portal hypertension-related gastrointestinal bleeding. The literature regarding splenic vein stenting for sinistral portal hypertension-related ascites is less robust. Technical and clinical success in the current case suggests that splenic vein recanalization may be a safe and viable option in other sinistral portal hypertension-related symptomatology. Level of Evidence: Level 4, Case Report.
机译:Sinistral门静脉高血压导致脾静脉的梗阻或狭窄,其特征在于正常的门静脉压力和肝功能试验。胃肠道出血是治疗最常见的呈现和迹象。虽然Sinistral门静脉高血压相关的Chylous腹水很少见,但几种病例描述了与门静脉的静脉,而不是脾静脉,再生化。脾切除术治疗尖锐物门高血压相关出血有效,尽管最近的研究已经评估了脾静脉支架和脾动脉栓塞,作为微创治疗替代品。脾静脉支架可能是其他呈罪的宿主高血压术语的可行选择。一个59岁的绅士,患有坏死性胆结石胰腺炎的历史,称为经常性乳糜腹水的介入放射学。对腹水的分析表明甘油三酯水平为1294×mg / dL。计算机断层扫描显示脾脏和优异的肠系膜静脉狭窄。 The patient elected to undergo minimally invasive transhepatic portal venography, which confirmed the presence of splenic vein and superior mesenteric vein stenosis.脾静脉的静脉静脉显示出逆转门静脉流动,多副侧侧和14毫米的压力梯度。放置了两个10?×40?40毫米码支架,减少了压力梯度至7?mmhg并解决了PortoSystemic侧支。在6个?几个月随访中,患者没有反复发作的腹水发作。目前案例突出了用经脾静脉支架治疗的尖锐物门高血压相关犬腹水的成功治疗。据报道,12个月的脾静脉支架Patent率为92.9%。脾静脉支架的速度为7.1%,脾脏切除术的16%和脾动脉栓塞的47.8%均已涉及到尖锐物门高血压相关的胃肠道出血。关于Sinistral门静脉高血压相关腹水的脾静脉支架的文献较小。目前案例中的技术和临床成功表明,脾静脉再生可能是其他尖叫门诊高血压相关的症状学中的安全和可行的选择。证据水平:4级,案例报告。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号